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Abstract 
Review on t(8;16)(p11;p13) KAT6A/CREBBP, with 
data on clinics, and the genes implicated. 
Clinics and pathology 
Disease 
Acute myeloid leukemia (AML) including AML-
M4, AML-M5a/M5b; Treatment related AML (t-
AML). 
Note 
In t-AML with t(8;16), patients often had a previous 
history of solid tumour (breast cancer) or 
haematological diseases (CMML, lymphomas). 
Phenotype/cell stem origin 
AML with t(8;16) may arise from an early stem cell 
with myeloid and monoblastic differentiation 
potential. 
Epidemiology 
Rare disease: a hundred and twenty cases have been 
reported in Mitelman database; (<1% of AML); 
found in children (median age at diagnosis: 1.2 
years) and adults (median age at diagnosis: 59.4 
years) with a female predominance (2/3). 
Clinics 
Disseminated intra vascular coagulation may be 
present; extramedullary infiltration; 20% of the cases 
could be therapy-related. 
Cytology 
Blast cells present a myelomonocytic stage of 
differentiation, and are characterized by a 
phenomenon of erythrophagocytosis with strong 
peroxidase and esterase activities. 
Immunophenotyping reveals CD4, CD14, CD13, 
CD33, CD56 and HLA-DR positives; CD34, CD117 
and CD133 negatives. 
t(8;16)(p11;p13) G- banding (left) - Courtesy Thomas Smol 
and Marie-Agnès Collonge-Rame (top), Jean-Luc Lai 
(second row) and Charles D. Bangs (third and bottom row), 
R- banding (right) - Courtesy Thomas Smol and Marie-
Agnès Collonge-Rame (top) and Jean-Luc Lai (second 
row), and ideogram (bottom right) - Courtesy Charles D. 
Bangs. 
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The t(8;16) has been cloned and shown to fuse the MOZ (monocytic leukemia zinc finger) gene at 8p11.2 to the CBP (CREB 
binding protein) gene at 16p13.3. The MOZ gene has also been found to be involved in variant translocations t(8;19)(p11;q13) 
and t(8;22)(p11;q13) and inv(8)(p11q13) translocations associated with M5/M4 AML.This translocation is associated with AML 
M5/M4. In the majority of cases it is associated with features of hemophagocytosis by leukemic cells, particularly 
erythrophagocytosis - Text and iconography Courtesy Georges Flandrin 2001. 
 
 
t(8;16)(p11;p13) : FISH with BAC KAT6A RP11-313J18 (8p11-21) probe (Amplitech) in red and BAC RP11-489O1 (16p13.11) 
probe (Amplitech) in green - Courtesy Thomas Smol and Marie-Agnès Collonge-Rame. 
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The prognosis is poor.  
In published series, death of patients occurs in half 
of the cases during the first 10 months after diagnosis 
due to infections or bleeding; survival is often less 
than 1 year but spontaneous remission has occurred 
(at least) once. 
Cytogenetics 
Additional anomalies 
Sole anomaly in 53.3% of cases; in 23.3% of cases, 
single additional abnormality: +8 ,various; in 23.3% 
of cases: complex karyotype; rare chromosome 7 
abnormalities, often in t-AML. 
Variants 
Complex variant t(8;16;V) may occur and has been 
described on rare occasions.  
8p11 may have other partners: t(8;22)(p11;q13) 
which involve EP300 in 22q13, EP300 is a 
homologue of CREBBP with acetyltransferase 
activity; t(8;19)(p11;q13.3) which should involve 
LEUTX on 19q13 (found in one t-AML case); 
inv(8)(p11p13) which leads to MYST3- NCOA2 
fusion; t(8;20)(p11;q13) leading to MYST3- 
NCOA3 fusion. 







KAT6A is also known as MYST3, or MOZ 
(monocytic leukemia zinc finger). 
DNA/RNA 
KAT6A gene is composed of 17 exons, with a 
MYST domain, located in exons 9-14, that remains 
intact in the t(8;16) translocations. 
Protein 
KAT6A gene encodes for a nuclear protein with 
histone acetyltransferase (HAT) due to MYST 





CREBBP is also known as CBP. 
DNA/RNA 
CREBBP is composed of 31 exons. 
Protein 
The protein encoded shows intrinsic histone 
acetyltransferase activity and shares regions of very 
high sequence similarity with protein p300. 




5' KAT6A - 3' CREBBP or 5' CREBBP - 3' KAT6A.  
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H1/5: Histone H1/5-like; ZF: zinc finger domain; HAT: Histone Acetyltransferase; S: serine-rich domain; QP: glutamine and 
proline-rich domain; M: methionine-rich domain; RID: receptor-interacting domain; CH1-2-3: cysteine and histidine-rich domain; 
KIX: binding site of CREB; Bd: bromodomain; Q: glutamine-rich domain. 
 
Transcript  
Five KAT6A -CREBBP transcripts have been 
descripted: type I (KAT6A exon 16 - CREBBP exon 
3); type II (KAT6A exon 16 - CREBBP exon 4); type 
III (KAT6A exon 17 - CREBBP exon 2 or 4); type 
IV (KAT6A exon 15 - CREBBP exon 4); 
type V (KAT6A exon 15 - CREBBP exon 5). Type I 
transcript is the most frequent fusion product. 
Reciprocal transcripts CREBBP- KAT6A: type I 
(CREBBP exon 2 - KAT6A exon 17); type IV 
(CREBBP exon 3 - KAT6A exon 16) are also found. 
Fusion protein 
Description 
The breakpoint for KAT6A is amino acid 1.013 or 
amino acid 1.117 (in the acidic domain).  
Fusion protein loses part of acidic domain in C-
terminal. HAT domains in KAT6A and  CREBBP 
are conserved. 
Oncogenesis 
t(8;16) AML are characterized by overexpression of 
HOXA9, HOXA10, and MEIS1; upregulation of 
RET and PRL; downregulation of CCND2, STAT5 
and WT1.  
They share similarities with MLL-rearranged 
leukemias suggesting a partially common 
leukemogenic pathway. 
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